5 articles tagged with "drug pricing"
The Trump administration is negotiating new drug-pricing agreements with smaller pharmaceutical companies, influenced by potential tariffs.
Eli Lilly's leadership has expressed clear opposition to the White House's initiative to codify drug pricing reforms, particularly the 'most favored nation' proposal.
The White House has initiated discussions on drug pricing reforms by sharing drafted legislative text with major pharmaceutical companies, while also addressing Chinese biotech licensing.
Recent comments from a senior health official during the Trump administration reveal critical flaws in the proposed most-favored nation drug pricing plan, alongside insights into Gilead's latest deal.
The White House is increasing its efforts to secure drug pricing reforms in Congress, focusing on a 'most-favored nation' policy that could reshape pharmaceutical pricing structures.